Exscientia spends SoftBank's cash in bid to edge out AI rivals
Exscientia is sprinting to win the great AI biotech race.
The UK company, having long labored on small discovery deals with large pharmas, raised up to $525 million in a Series D led by the infamous Japanese conglomerate SoftBank in April and followed it up less than a month later with a Bristol Myers Squibb deal that paid $50 million cash and $1.2 billion in milestones.
Now, the Oxford spinout is splurging on a shiny new tool. On Monday they announced they purchased the three-year-old molecule-screening biotech Allcyte, a longtime collaborator, for $60.6 million in cash and stock.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.